The US patent has come through for Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)’s novel DurAVR™ transcatheter heart valve.
The medtech company today welcomed news that the US Patent and Trademark Office has issued a utility patent for its heart valve technology.
First-in-class
DurAVR™ THV is a first-in-class biomimetic valve designed to mimic the performance of a healthy human heart valve.
The patent – number 11,622,853, expiring on September 30, 2042 – further confirms that the company has developed a differentiated heart valve technology through its innovative single-piece, shaped-tissue design.
Anteris believes the unique aspects of the DurAVR™ design, including the single-piece valve construction, account for the excellent clinical results to date.
Competitive position
“The patent signifies the extraordinary work by our team of engineers around the world responsible for the design of DurAVR™ THV,” said CEO Wayne Paterson.
“The granting of this patent enhances the broad IP protection of DurAVRTM, strengthening our competitive position in the TAVR field.”
Read more about the global unmet need Anteris is working to address.
About Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF)
Anteris is a structural heart company working on clinically superior and durable solutions through better science and better design.
Anteris’ DurAVRTM 3D single-piece aortic heart valve replacement addresses the needs of today’s younger and more active aortic stenosis patients, delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of the DurAVRTM 3D single-piece aortic heart valve, have the potential to deliver life-changing treatment to aortic stenosis patients worldwide.